167 related articles for article (PubMed ID: 33889510)
1. Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Suzuki M; Kasajima R; Yokose T; Ito H; Shimizu E; Hatakeyama S; Yokoyama K; Yamaguchi R; Furukawa Y; Miyano S; Imoto S; Yoshioka E; Washimi K; Okubo Y; Kawachi K; Sato S; Miyagi Y
Transl Lung Cancer Res; 2021 Mar; 10(3):1292-1304. PubMed ID: 33889510
[TBL] [Abstract][Full Text] [Related]
2. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
Suzuki M; Yazawa T; Ota S; Morimoto J; Yoshino I; Yamanaka S; Inayama Y; Kawabata Y; Shimizu Y; Komatsu M; Notohara K; Koda K; Nakatani Y
Histopathology; 2015 Dec; 67(6):806-16. PubMed ID: 25851923
[TBL] [Abstract][Full Text] [Related]
3.
Suzuki M; Kasajima R; Yokose T; Shimizu E; Hatakeyama S; Yamaguchi K; Yokoyama K; Katayama K; Yamaguchi R; Furukawa Y; Miyano S; Imoto S; Shinozaki-Ushiku A; Ushiku T; Miyagi Y
Transl Lung Cancer Res; 2023 Aug; 12(8):1738-1751. PubMed ID: 37691868
[TBL] [Abstract][Full Text] [Related]
4. Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the Lung.
Li Y; Xi SY; Yong JJ; Wu XY; Yang XH; Wang F
Am J Surg Pathol; 2021 Nov; 45(11):1464-1475. PubMed ID: 34138800
[TBL] [Abstract][Full Text] [Related]
5. Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung.
Zhang S; Yin H; Zhang J; Yang L; Yang G; Jia J; Jiao Y; Ying J; Wang Y
Thorac Cancer; 2021 Oct; 12(20):2789-2795. PubMed ID: 34464028
[TBL] [Abstract][Full Text] [Related]
6. Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study.
Zhang J; Sun J; Liang XL; Lu JL; Luo YF; Liang ZY
J Thorac Dis; 2017 Jul; 9(7):2071-2078. PubMed ID: 28840008
[TBL] [Abstract][Full Text] [Related]
7. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review of fetal adenocarcinoma of the lung.
Ricaurte LM; Arrieta O; Zatarain-Barrón ZL; Cardona AF
Lung Cancer (Auckl); 2018; 9():57-63. PubMed ID: 30197546
[TBL] [Abstract][Full Text] [Related]
9. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules.
Nakatani Y; Masudo K; Miyagi Y; Inayama Y; Kawano N; Tanaka Y; Kato K; Ito T; Kitamura H; Nagashima Y; Yamanaka S; Nakamura N; Sano J; Ogawa N; Ishiwa N; Notohara K; Resl M; Mark EJ
Mod Pathol; 2002 Jun; 15(6):617-24. PubMed ID: 12065775
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of Low-Grade Fetal Adenocarcinoma and Adenocarcinoma in situ of the Lung Harboring Different Genetic Mutations: A Case Report and Review of Literature.
Liu S; Wang J; Luo X; Li X; Miao Y; Wang L; Li Q; Qiu X; Wang EH
Onco Targets Ther; 2020; 13():6675-6680. PubMed ID: 32753900
[TBL] [Abstract][Full Text] [Related]
12. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
15.
Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
[No Abstract] [Full Text] [Related]
16. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
19. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
20. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Wang JY; Xiu J; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Oberley M; Spetzler D; Shen L; Korn WM; Lenz HJ
Ann Oncol; 2021 Jul; 32(7):906-916. PubMed ID: 33798656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
